Circulating tumor cells (CTCs) have emerged as a key prognostic biomarker for breast cancer, with their role becoming more pronounced in metastatic cases. In metastatic breast cancer, having five or m...

CDK4/6 inhibitors (CDK4/6i) have significantly impacted on the treatment of HR+ HER2 negative (HER2-) metastatic breast cancer (BC) when combined with…

npj Breast Cancer - Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer

The clinical implications of molecular heterogeneity in HER2-positive breast cancer remain to be explored. Here, the authors investigate the transcriptomic landscape of HER2-positive breast cancer pat...

About the survey This survey aims to evaluate oncologists' attitudes, practices, and barriers to the use of liquid biopsy in clinical care. Your participation in this survey is voluntary. The survey ...

The study explored endocrine resistance by leveraging machine learning to establish the prognostic stratification of predicted Circulating tumor cells…